Cell Transplantation (Mar 2023)

Expandable Sendai-Virus-Reprogrammed Human iPSC-Neuronal Precursors: Post-Grafting Safety Characterization in Rats and Adult Pig

  • Yoshiomi Kobayashi,
  • Michiko Shigyo,
  • Oleksandr Platoshyn,
  • Silvia Marsala,
  • Tomohisa Kato,
  • Naoki Takamura,
  • Kenji Yoshida,
  • Akiyoshi Kishino,
  • Mariana Bravo-Hernandez,
  • Stefan Juhas,
  • Jana Juhasova,
  • Hana Studenovska,
  • Vladimir Proks,
  • Shawn P. Driscoll,
  • Thomas D. Glenn,
  • Samuel L. Pfaff,
  • Joseph D. Ciacci,
  • Martin Marsala

DOI
https://doi.org/10.1177/09636897221107009
Journal volume & issue
Vol. 32

Abstract

Read online

One of the challenges in clinical translation of cell-replacement therapies is the definition of optimal cell generation and storage/recovery protocols which would permit a rapid preparation of cell-treatment products for patient administration. Besides, the availability of injection devices that are simple to use is critical for potential future dissemination of any spinally targeted cell-replacement therapy into general medical practice. Here, we compared the engraftment properties of established human-induced pluripotent stem cells (hiPSCs)-derived neural precursor cell (NPCs) line once cells were harvested fresh from the cell culture or previously frozen and then grafted into striata or spinal cord of the immunodeficient rat. A newly developed human spinal injection device equipped with a spinal cord pulsation-cancelation magnetic needle was also tested for its safety in an adult immunosuppressed pig. Previously frozen NPCs showed similar post-grafting survival and differentiation profile as was seen for freshly harvested cells. Testing of human injection device showed acceptable safety with no detectable surgical procedure or spinal NPCs injection-related side effects.